“These are five stocks for aggressive investors looking to get share count leverage on biotech companies that have sizable upside potential,” says the author of today’s article of the five biotech stocks he highlights – all of which are trading under the $10 level and are rated “Overweight” at Oppenheimer. For these five biotech stocks, CLICK HERE.
“These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential,” says the author of today’s article of the five stocks he highlights – all of which have Buy ratings at major firms and are trading under the $10 level. For these five stocks –which include an intriguing biotech play with…
“While more suited for aggressive investors, and with the number of new traders skyrocketing over the past year and making good ideas to trade even harder to find, these could prove exciting additions for traders looking for solid alpha potential,” says the author of today’s article of the five Buy-rated energy stocks trading under $10 that he proceeds to highlight.…
“These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential,” declares the author of today’s article of the five Buy-rated stocks trading under $10 that he highlights. Among them are a late-stage pharmaceutical company focused on developing potential new therapies for cancer, a security technology company that provides email encryption…
While more suited for aggressive investors, and with the number of new traders skyrocketing over the past year and making good ideas to trade even harder to find, these could prove exciting additions for traders looking for solid alpha potential,” says the author of today’s article of the five Buy-rated stocks currently trading under $10 that he proceeds to highlight.…